The popularity of Sildenafil initially drove a period of growth for pharma, nevertheless recent shifts present a uncertain scenario for shareholders. Lower-cost alternatives are reducing revenue, and ongoing patent https://laytnxyjd287620.blogginaway.com/41940331/sildenafil-and-the-pharmaceutical-industry-a-precarious-investment